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Angiogenesis is the process of formation of new vasculature; an important process in various pathological conditions. 
The study is focused on the screening of herbal plants targeting angiogenesis. The ethanolic extract of plant Bombax ceiba 
(EEBC) and Erythrina variegata (EEEV) were used. The experimental methods included regenerative angiogenesis assay in 
adult zebrafish and developmental angiogenesis assay in zebrafish embryos. For the regenerative angiogenesis assay, the 
regeneration of amputated fin length was evaluated. The adult zebrafishes were divided into 5 treatment groups of 8 fishes in 
each group. In developmental angiogenesis assay, various phenotype changes in embryos were observed. The embryos were 
divided into 5 groups with 12 embryos in each group. For both assays grouping was; group I vehicle control (DMSO), group 
II high dose of EEBC, group III low dose of EEBC, group IV high dose of EEEV and group V low dose of EEEV. The 
results of both the assays suggest that EEBC showed significant (p <0.05) pro-angiogenic activity while EEEV showed 
significant (p <0.05) anti-angiogenic activity. Therefore EEBC can prove beneficial in diseases related to insufficient 
angiogenesis like in management of wound healing while, EEEV in diseases related to excessive angiogenesis like 
management of cancer. 
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Introduction: 
Bombax ceiba is one of the important medicinal 
plants and it belongs to the family Bombaceae. It is 
known by different names such as silk cotton tree, red 
cotton tree, Indian kapok tree, shalmali, semal, and 
shimul etc. The plant is found in the tropical and 
subtropical region in Asia especially in India, Sri 
Lanka, Pakistan, Malaysia, Myanmar and in 
Bangladesh. It has many medicinal uses in the 
traditional system of medicine such as Ayurveda, 
Siddha, and Unani1,2. According to Ayurveda,  
B. ceiba has many medicinal properties like a 
stimulant, astringent, hemostatic, aphrodisiac, 
diuretic, antidiarrheal, cardiotonic, emetic, demulcent 
and antipyretic etc3,4. Different parts of the plant are 
used for different purpose. A paste of leaves and 
flowers of this tree is applied as an external 
application for skin irritation. Seed oil is used for 
manufacturing of soaps and lubrication substances. 
Seeds are applied on the skin in smallpox and chicken 
pox. Leaves are used as a laxative and hematinic. The 
bark of the plant is used for wound healing5.  
Erythrina variegata is also known as the ‘Indian coral 
tree’ in Asia or ‘tropical coral’ in the Pacifics and it 
belongs to the family Fabaceae. It is an important 
multipurpose tree species and thrives well in the arid 
and semiarid region. It is found in many tropical and 
subtropical regions. E. variegata has been used in folk 
medicine for treatment of insomnia, malarial fever, 
helminths, venereal disease, asthma and toothache6-8. 
The alkaloid erythroidine abundant in E. variegata 
was used as a muscle relaxant9. The juice of  
E. variegata stimulates lactation and is useful in 
dysmenorrhea. The root extract possesses anti-
microbial activity. The bark of the plant is used as a 
laxative, diuretic, expectorant, liver tonic and anti-
rheumatoid. A warm poultice of the leaves is applied 
externally to relieve rheumatic joint pain. The leaf 
extract is also used as a nervine sedative, collyrium in 
ophthalmia, anti-asthmatic, anti-epileptic, nematicidal, 








Angiogenesis is the process of formation of blood 
vessels from pre-existing blood vessels; mediated by 
the endothelial cells that line the blood vessels. 
Endothelial cells in the process of angiogenesis 
undergo complex sequence events that include the 
secretion of metalloproteases and other matrix-
degrading enzymes, cell migration into the newly 
created space, endothelial cell division and 
proliferation, and vessel formation12. These are well- 
regulated processes involving a number of stimulators 
such as fibroblast growth factor, vascular endothelial 
growth factor (VEGF), platelet-derived growth factor 
(PDGF), angiopoietins, activators of integrins and 
inhibitors such as thrombospondin, angiostatin, and 
endostatin; thus plays important role in the normal 
physiology of angiogenesis13,14. Angiogenesis is an 
important step in various pathological conditions like 
tumour progression because angiogenesis provides 
nutrients that maintain the viability of diseased tissue. 
Angiogenesis associated with a tumour allows a 
tumour to maintain its growth and also facilitates 
metastatic spreading by establishing a connection to 
the existing vasculature. In addition to angiogenesis, it 
has become clear that inflammation is a key 
component in cancer insurgence that can promote 
tumour angiogenesis. The difference between 
angiogenesis in normal condition and angiogenesis in 
diseased condition is blood vessels formed in diseased 
tissue are highly disorganized and their walls have 
numerous openings; and because of this tumor vessels 
are not able to mature through the recruitment of 
smooth muscle cells and pericytes, leading to the 
formation of leaky vessels in the tumor15,16. In the 
case of congestive heart failure, chronic wound and 
non-union fracture the angiogenesis is insufficient 
where the growth of blood vessels and circulation of 
blood is not proper. It leads to tissue death and 
delayed wound healing followed by organ 
amputation. To overcome this problem the 
angiogenesis process is needed to be improved17. 
The plant B. ceiba is reported with wound healing 
activity5 while E. variegata is reported with anti-
cancer activity9, indicating them with the probable 
modulatory action of angiogenesis. Thus the effect on 
angiogenesis of this plant can prove as the rationale 
behind their reported activities as either in wound 
healing or anti-cancer action. In the present study, the 
plants selected were B. ceiba and E. variegata to 
evaluate their potential effects on angiogenesis 
process.  
Material and Methods 
Plant material 
The plant materials of B. ceiba bark and  
E. variegata leaves were collected from Rajesh 
chemicals, Mumbai. Both the powder materials were 
authenticated from Taxonomist Dr. H. M. Pandit 
(Formerly Head and Associate Professor of Botany, 
Department of Botany, Guru Nanak Khalsa College, 
Mumbai). Voucher specimens number namely vdj p 
1060432 (Bark powder of B. ceiba L.) and vdj p 
1060429 (Leaf powder of E. variegata L.) were 
deposited in Department of Pharmacology at Bharti 
Vidyapeeth’s College of Pharmacy, Navi Mumbai. 
The powdered plant material was macerated for 8 
hours using the solvent petroleum ether for defatting 
of the material. The crude extract was obtained by 
placing 50 g of powder in the soxhlet extractor18 using 
ethanol at 40 °C for 48 hours. The crude extract of the 
plant was further evaporated in the rotavac evaporator 
to get free-flowing powder. The typical yield obtained 
for a crude ethanolic extract of B. ceiba was 21.61 % 
w/w and for ethanolic extract of E. variegata was  
17.9 % w/w.  
 
Experimental animal 
The adult and wild-type of zebrafishes were 
procured from a local supplier. The fishes were kept 
in the tanks and supplied with atmospheric air and 
with spirulina granules, dried earthworms and 
tetramine flakes 3 times daily. Sodium thiosulphate 
was added to dechlorinate the tank water. The pH of 
the water was maintained to neutral and 12 hours 
light/dark cycle in specialized zebrafish tanks was 
maintained. Fishes were acclimatized for 15 days 
prior to the study.  
The zebrafish embryos were procured from a local 
supplier and kept in embryo medium. The 
composition of embryo medium is sodium chloride 
(0.29 % w/v), potassium chloride (0.013 % w/v), 
calcium chloride (0.049 % w/v), magnesium sulphate 
(0.081 % w/v) in distilled water.  
 
Experimental procedure  
Regenerative angiogenesis assay 
The zebrafishes were divided into 5 treatment 
groups; each group was having 8 fishes. Group, I was 
treated with vehicle control (25 µL/ g of DMSO per g 
of zebra fish), Group II and III were treated with 0.43 
and 0.2 mg of EEBC per g of zebrafish respectively 
while group IV and V was treated with 0.38 and  
0.19 mg of EEEV per g of zebrafish respectively. The 




one-tenth of LD50 was used for main study 19. On the 
1st day of study, fishes were anaesthetized by 2-
phenoxy ethanol and the caudal fin was amputated up 
to 50 % of its fin length. The dose was administered 
by oral route using hamilton syringe of capacity 10 
µL on every alternate day to the 7th day of study. Post 
amputed images were taken on the 3rd day and 7th day 
by Motic digital microscope with Image plus 2.0 
software (Model: DMWB1-222ASC) and length of 
the regenerated fin was measured and calculated20.  
 
Developmental angiogenesis in zebrafish embryos 
The embryos were divided into 5 treatment groups; 
each group was having 12 embryos. Each embryo was 
transferred in an individual well of 96 well microtiter 
plate. Group I was treated with vehicle control (0.03 µL 
DMSO), Group II and III was treated with 0.020, 
0.015 ug of EEBC per μL of DMSO respectively 
while group IV and V was treated with 0.030, 0.020 
ug of EEEV per μL of DMSO, respectively. Various 
changes in phenotype such as tail bending, delayed 
hatching, abnormal yolk sac, abnormal vasculature, 
pericardial edema, and haemorrhages were observed 
and images were taken at 24, 48 and 72 hpf by using 
Motic digital microscope with Image plus 2.0 
software (Model: DMWB1-222ASC). The survival 
rate was recorded up to 96 hpf21.  
Results 
Regenerative angiogenesis assay 
The effect of EEBC on zebrafish caudal fin was 
studied up to 7 days. On day 1, the caudal fin was 
amputated up to 50 % and the dose was given on 
every alternate day to the 7th day. The images of 
regenerated fin were taken by motic digital 
microscope on day 3 and 7 (Fig. 1). The length of the 
regenerated caudal fin was measured and the graph 
was plotted. (Fig. 2 and 3) 
 
Developmental angiogenesis assay 
After the drug treatment, the embryos were 
observed after 24, 48 and 72 hpf using Motic digital 
microscope. Various phenotype changes such as tail 
bending, abnormal yolk sac, abnormal vasculature, 
haemorrhages, pericardial edema and delayed 
hatching were recorded at 24, 48 and 72 hpf. The 
survival rate was observed after 24, 48, 72 and 96 hpf 
(Fig. 4). The changes in phenotypes were observed 
after 72 hpf (Fig. 5 and 6).  
 
Discussion 
Regenerative angiogenesis assay 
Zebrafish has emerged as a powerful vertebrate 
genetic model to study regeneration as it can 
regenerate one fifth to the heart ventricles, pancreas 
 
 
Fig. 1 — Images of the length of the regenerated fin of dorsal, ventral and cleft region on the 3rd and 7th day post amputation of EEBC 
and EEEV 




and grows caudal fin22. It is useful in understanding 
the molecular and cellular mechanisms of 
regeneration, based on their regenerative ability. The 
caudal fin is composed of bony rays, mesenchymal 
tissue, blood vessels, and nerves, enclosed by the 
epidermis and can regenerate fully after resection. 
Lost caudal fin tissue in zebrafish is recovered 
through epimorphic regeneration i.e. blastema 
formation and restoration of tissue which resembles 
the wound healing process in humans. The adult 
zebrafish tail (caudal) fin has good regeneration 
ability making it a model of choice for studying 
regenerative angiogenesis in mammals23. In zebrafish, 
the process of fin regeneration includes various 
pathways including FGF (Fibroblast growth factor) 
which plays important role in blastema formation, 
MAP kinase etc24,25. Briefly regeneration of caudal fin 
after amputation having three regeneration stages; 
stage 1 is Wound healing [0-1 days post amputation 
(dpa)], stage 2 is formation of the regeneration 
blastema (1-3 dpa), a mass of high proliferation 
lineage-restricted mesenchymal progenitor cells; stage 
3 is regenerative outgrowth and patterning of new 
tissue (>3 dpa)26. 
In the current study; the zebrafishes of the vehicle 
control group showed normal regeneration of 
amputated fin. The effect of EEBC at both 0.43 and 
0.2 mg dose on zebrafish tail fin regeneration showed 
positive result i.e. elongation of the tail fin which was 
significantly more than the vehicle control group; thus  
 
showing pro-angiogenic activity. This activity may be 
attributed to the activation of pro-angiogenic factors. 
While the effect of EEEV at both 0.38 and 0.19 mg 
doses showed negative result i.e. inhibition of 
regeneration of tail fin significantly (p <0.05 
computed using one way ANOVA followed by 
Tukey’s multiple comparison tests) less than the 
 
Fig. 2 — Graphical representation of the effect of EEBC and
EEEV on regenerative angiogenesis assay on day 3 
 
 
Fig. 3 — Graphical representation of the effect of EEBC and
EEEV on regenerative angiogenesis assay on day 7 
 
 
Fig. 4 — Percent survival rate at 24, 48, 72, and 96 hpf 




vehicle control group; thus showing anti-angiogenic 
activity. Thus EEEV probably is acting via either 
complete inhibition or suppression of pro-angiogenic 
factors like PDGF, VEGF or blocking of their 
respective receptors27.  
Developmental angiogenesis assay 
The zebrafish embryo shows a strong similarity to 
that of other vertebrates28. In zebrafish embryonal phase 
at the 13 somite-stages, endothelial cell precursors 
migrate from the lateral mesoderm and originate into the 
vasculature leading to the development of a single blood 
circulatory system at 24 hpf. Blood vessel develops 
during the subsequent days by angiogenesis. In the 
process of angiogenesis, the intersegment vessels of 
the trunk sprout from the dorsal aorta at 20 hpf. 
Substantial vein vessels originate from the duct of the 
curvier area at 48 hpf and will form a vascular plexus 
across most of the dorsal-lateral aspect of the yolk sac 
during the next 24 hours29. The EEBC treated group 
showed 90-100 % survival rate and very fast hatching 
rate as well. Very less number of zebrafish embryos 
showed the phenotypical changes till 96 hours post 
fertilization. The result obtained by zebrafish embryos 
showed significant (p <0.05) growth of new blood 
vessels and also a good development of organs of a 
treated group of zebrafish embryos. The drug showed 
pro-angiogenic activity. While the EEEV treated 
group showed less survival rate and also showed more 
developmental abnormalities. The results are in 
accordance with the angiogenesis studies on plant B. 
ceiba and E. variegata conducted on the fertile white 
leghorn chicken eggs30.  
 
 
Fig. 5 — Changes in phenotype at 72 hpf 
 
 
Fig. 6 — Graphical representation of phenotype changes at 72 hpf 





The angiogenesis assay results suggest that the plant 
B. ceiba possess anti-angiogenic activity while  
E. variegata possesses pro-angiogenic effect both in 
developmental and regeneration angiogenesis process. 
Further molecular studies can be carried out on the 
plant or the potential isolate(s) to understand and 
justify detailed mechanism of action on the 
angiogenesis process. Thus these plants can be a 
potential source for a drug of interest in the treatment 
of diseases related either insufficient angiogenesis such 
as coronary heart diseases, chronic wound, wound 
healing in ulcer and diabetes or in the treatment of 
diseases related to the excessive angiogenesis such as 
cancer, rheumatoid arthritis, and psoriasis. 
 
References 
1 Vaidyaratnam, P S V, Indian medicinal plants a compendium 
of 500 species (Orient Longman Private Limited, Chennai), 
2005, 3, 264-265. 
2 Ravi V, Patel S S, Verma K, Dutta D and Saleem T S M, 
Hepatoprotective activity of Bombax ceiba Linn against 
Isoniazid and Rifampicin induced toxicity in experimental 
rats, Int J Appl Res Nat Prod, 2010, 3(3), 19-26.  
3 Sarita K, Greindra G and Shailsh G, Pharmacognostic and 
pharmacological profile of Bombax ceiba, Asian J Pharm 
Educ Res, 2017, 6(3), 16-27. 
4 Pankaj H C and Somshekhar S K, Bombax ceiba Linn.: 
Pharmacognosy, ethnobotany and phyto-pharmacology, 
Pharmacog Commun, 2012, 2(3), 2-9. 
5 Verma R, Devre K, Gangrade T, Gore S and Gour S, A 
Pharmacognostic and pharmacological overview on Bombax 
ceiba, Sch Acad J Pharm, 2014, 3(2), 100-107. 
6 Kumar A, Lingadurai S, Jain A and Barman N R, Erythrina 
Variegata Linn: A review on morphology, phytochemistry 
and pharmacological aspects, Pharmacogn Rev, 2010, 4(8), 
147-152.  
7 Suryawanshi H P and Patel M, Traditional uses, medicinal 
and phytopharmacological properties of Erythrina indica 
lam: An overview, Int J Res Ayurveda Pharm, 2011, 2(5), 
1531-1533. 
8 Telikepalli H, Gollapudi S R, Keshavarz-Shokri A, 
Velazquez L, Sandmann, R.A, et al., Isoflavonoids and a 
cinnamylphenol from root extracts of Erythrina variegata, 
Phytochemistry, 1990, 29, 2005–2007. 
9 Payne L, The alkaloids of Erythrina: Clonal evaluation and 
metabolic fats, Ph D Thesis, Louisiana State University, 
1991. 
10 Rao V, Chemical examination of Erythrina indica (White 
variety), Curr Sci, 1945, 14, 198-198. 
11 Kobayashi M, Mahmud T, Yoshioka N, Shibuya H and 
Kitagawa I, Indonesian medicinal plants XXI Inhibitors of 
Na+/H+ exchanger from the bark of Erythrina variegata and 
the roots of Maclura cochinchinensis, Chem Pharm Bull, 
1997, 45(10), 1615–1619. 
12 Areck A, Andrew A, Andrea T and Howard P, Molecular 
mediators of angiogenesis, J Burn Care Res, 2010, 31(1), 
158, 1-28. 
13 Kelly E J and Traci A W, Vascular endothelial growth factor 
and angiogenesis in the regulation of cutaneous wound 
repair, Adv wound care (New Rochelle), 2014, 3(10), 647-
661. 
14 Constanza E, Patricio C and Verónica A, The influence of platelet- 
derived products on angiogenesis and tissue repair: A concise 
update, Front physiol, 2015, 6(290), 1-7. 
15 Terman B and Stoletov K, VEGF and tumor angiogenesis, 
Einstein J Biol Med, 2001, 18, 59-66. 
16 Noonan D, Benelli R and Albini A, Angiogenesis and cancer 
prevention: A vision, recent results in cancer research, 
(Springer-Verlag Berlin Heidelberg), 2007, 174, 219-224. 
17 Fan T, Yeh J, Leung K and Yeu P, Angiogenesis: from plants to 
blood vessels, Trends Pharmacol Sci, 2006, 27(6), 297-309. 
18 Agrawal S S and Paridhavi M, Extraction, isolation and 
analysis of phytopharmaceuticals, in Herbal drug 
technology, 2nd edn, (University press, India), 2012, 324-326. 
19 OECD guideline for testing of chemicals, section 2, Effects 
on biotic systems, Fish, Acute toxicity test, Test no. 203, July 
1992. 
20 Shete S, Mundada S and Dhande S, Comparative effect of 
crude extract of Parkia biglandulosa and its isolate on 
regenerative angiogenesis in adult zebrafish model, Indian 
drug, 2017, 54(12), 60-66. 
21 Priyanka K, Deepali J and Swati D, Acute toxicity testing of 
synthesized pyrazoline derivatives in adult zebrafish, Int J 
Pharm Sci Res, 2018, 9(1), 277-281. 
22 Gemberling M, Bailey T J, Hyde D R and Poss K D, The 
zebrafish as a model for complex tissue regeneration, Trends 
genet, 2013, 29(11), 611-620.  
23 Rathinasamy V, Paneerselvan N and Ragunathan M, Effect of 
genistein on regenerative angiogenesis using zebrafish as 
model organism, Biomed Prev Nutr, 2014, 4(4), 469–474. 
24 Nakatani Y, Kawakami A and Kudo A, Cellular and 
molecular processes of regeneration with special emphasis 
on fish fins, Dev Growth Differ, 2007, 49, 145–154. 
25 Pfefferli C and Jaźwińska A, The art of fin regeneration in 
zebrafish, Regeneration, 2015, 2, 72–83.  
26 Chávez M, Aedo G, Fierro F, Allende M and Egana J, 
Zebrafish as an emerging model organism to study 
angiogenesisin development and regeneration, Front Physiol, 
7(56), 1-16. 
27 Marius R and Anca M C, Platelet-derived growth factor 
(PDGF)/PDGF receptors (PDGFR) axis as target for 
antitumor and antiangiogenic therapy, Pharmaceuticals 
(Basel), 2010, 3, 572-599. 
28 Hsin H C, Hong B Z, Shing L C and Duranjib C, The 
zebrafish model: Use in studying cellular mechanism for a 
spectrum of clinical disease entities, Curr Neurovasc Res, 
2007, 4, 111-120. 
29 Tobia C, DE Sena G and Presta M, Zebrafish embryo, a tool 
to study tumor angiogenesis, Int J Dev Biol, 2011, 55, 505-
509. 
30 Sneha S K, Varsha D J and Swati R D, Screening of drug 
targeting angiogenesis, World J Pharm Pharm Sci, 2017, 
6(10), 595-600. 
 
